- Home
- TNGX vs JMIA Comparison
TNGX vs JMIA Comparison
Compare TNGX & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- JMIA
- Stock Information
- Founded
- TNGX 2014
- JMIA 2012
- Country
- TNGX United States
- JMIA Germany
- Employees
- TNGX N/A
- JMIA N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- JMIA Catalog/Specialty Distribution
- Sector
- TNGX Health Care
- JMIA Consumer Discretionary
- Exchange
- TNGX Nasdaq
- JMIA Nasdaq
- Market Cap
- TNGX 351.2M
- JMIA 412.7M
- IPO Year
- TNGX N/A
- JMIA 2019
- Fundamental
- Price
- TNGX $6.01
- JMIA $4.29
- Analyst Decision
- TNGX Strong Buy
- JMIA Buy
- Analyst Count
- TNGX 6
- JMIA 2
- Target Price
- TNGX $12.20
- JMIA $7.88
- AVG Volume (30 Days)
- TNGX 2.7M
- JMIA 3.9M
- Earning Date
- TNGX 08-06-2025
- JMIA 08-05-2025
- Dividend Yield
- TNGX N/A
- JMIA N/A
- EPS Growth
- TNGX N/A
- JMIA N/A
- EPS
- TNGX N/A
- JMIA N/A
- Revenue
- TNGX $40,990,000.00
- JMIA $154,854,000.00
- Revenue This Year
- TNGX N/A
- JMIA $10.62
- Revenue Next Year
- TNGX N/A
- JMIA $7.08
- P/E Ratio
- TNGX N/A
- JMIA N/A
- Revenue Growth
- TNGX 10.09
- JMIA N/A
- 52 Week Low
- TNGX $1.03
- JMIA $1.60
- 52 Week High
- TNGX $12.02
- JMIA $15.04
- Technical
- Relative Strength Index (RSI)
- TNGX 76.36
- JMIA 64.65
- Support Level
- TNGX $5.34
- JMIA $4.09
- Resistance Level
- TNGX $6.40
- JMIA $4.62
- Average True Range (ATR)
- TNGX 0.50
- JMIA 0.34
- MACD
- TNGX -0.02
- JMIA 0.06
- Stochastic Oscillator
- TNGX 84.08
- JMIA 77.63
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.